Methylnaltrexone Mechanisms of Action and Effects on Opioid Bowel Dysfunction and Other Opioid Adverse Effects

Abstract

Spanish

French

OBJECTIVE:

To review the mechanisms of action of methylnaltrexone and its effects on opioid bowel dysfunction, as well as its effects on other opioid-induced adverse effects (ADEs), and its potential roles in clinical practice.

DATA SOURCES:

A literature search using the MEDLINE and Cochrane Collaboration databases for articles published between 1966 and March 2007 was performed. Additional data sources were obtained from manual searches of recent journal articles, book chapters, and monographs. An updated literature search showed no additional publications.

STUDY SELECTION AND DATA EXTRACTION:

Abstracts and original preclinical and clinical research reports published in the English language were identified for review. Review articles, commentaries, and news reports of this compound were excluded. Literature related to opioids, opioid receptors, opioid antagonists, methylnaltrexone, opioid-induced bowel dysfunction, constipation, nausea, and vomiting was evaluated and selected based on consideration of the support shown for the proof of concept, mechanistic findings, and timeliness. Fifty-eight original articles from preclinical studies and clinical trials using methylnaltrexone were identified. Pharmacologic action, benefits, and ADEs of methylnaltrexone were reviewed, with a focus on its effects on bowel dysfunction after opioids. Emphases were placed on its receptor binding activities and therapeutically relevant sites of action (peripheral vs central), in which peripheral opioid receptors in the body contribute to physiological and drug-induced effects.

DATA SYNTHESIS:

Morphine and related opioids are associated with a number of limiting ADEs, including opioid-induced bowel dysfunction. Methylnaltrexone, a quaternary derivative of naltrexone, blocks peripheral effects of opioids while sparing central analgesic effects. It is currently under late-stage clinical investigation for the treatment of opioid-induced constipation in patients with advanced illness. Reported results showed the drug to be generally well-tolerated. The rapid reversal of constipation is very encouraging. Hastening postoperative discharge may also be possible.

CONCLUSIONS:

Methylnaltrexone has the potential to prevent or treat opioid-induced peripherally mediated ADEs on bowel dysfunction without interfering with central analgesia. The study of methylnaltrexone leads to a greater understanding of the mechanisms of action of opioid pharmacology.

Keywords

methylnaltrexone opioid-induced bowel dysfunction opioid receptors opioids peripheral opioid antagonist

Get full access to this article

View all access options for this article.

References

1. Gowan

Hurtig

Fraser

Torbicki

Kitts

. Naloxone infusion after prophylactic epidural morphine: Effects on incidence of postoperative side-effects and quality of analgesia. Can J Anaesth 1988;35:143–8.

2. Culpepper-Morgan

Inturrisi

Portenoy

. Treatment of opioid-induced constipation with oral naloxone: A pilot study. Clin Pharmacol Ther 1992;52: 90–5.

3. Cheskin

Chami

Johnson

Jaffe

. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend 1995;39:151–4.

4. Sykes

. Using of oral naloxone in the management of opioid bowel dysfunction. In: Yuan

, ed. Handbook of opioid bowel syndrome. New York: Haworth Medical Press, 2005:175–95.

5. Brown

Goldberg

. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24:181–91.

6. Russell

Bass

Goldberg

Schuster

Merz

. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982;78:255–61.

7. Woods

Medzihradsky

Smith

Young

Swain

. Annual report: Evaluation of new compounds for opioid activity (1980). NIDA Res Monogr 1981;34:327–66.

8. Gmerek

Cowan

Woods

. Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther 1986;236:8–13.

9. Walker

Poulos

Cappell

. Role of central versus peripheral opioid receptors in analgesia induced by repeated administration of opioid antagonists. Psychopharmacology (Berl) 1991;104:164–6.

10.

10. Yuan

. Gastric effects of mu-, delta- and kappa-opioid receptor agonists on brainstem unitary responses in the neonatal rat. Eur J Pharmacol 1996;314:27–32.

11.

11. Yuan

Foss

. Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses. Neuropharmacology 1999;38:425–32.

12.

12. Jaffe

Martin

. Opioid analgesics and antagonists. In: Gilman

Rall

Nies

Taylor

, eds. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990:485–521.

13.

13. Bitar

Makhlouf

. Selective presence of opiate receptors on intestinal circular muscle cells. Life Sci 1985;37:1545–50.

14.

14. Choi

Billings

. Opioid antagonists: A review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 2002;24:71–90.

15.

15. Ouyang

Vos

Cohen

. Sites of action of mu-, kappa- and sigma-opiate receptor agonists at the feline ileocecal sphincter. Am J Physiol 1988;254:G224–31.

16.

16. Manara

Bianchetti

. The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol 1985;25: 249–73.

17.

17. Stewart

Weisbrodt

Burks

. Central and peripheral actions of morphine on intestinal transit. J Pharmacol Exp Ther 1978;205:547–55.

18.

18. Galligan

Burks

. Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Exp Ther 1983;226:356–61.

19.

19. Daniel

Sutherland

Bogoch

. Effects of morphine and other drugs on motility of the terminal ileum. Gastroenterology 1959;36:510–23.

20.

20. Burks

. Mediation by 5-hydroxytryptamine of morphine stimulant actions in dog intestine. J Pharmacol Exp Ther 1973;185:530–9.

21.

21. Tavani

Bianchi

Ferretti

Manara

. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: Evidence for local action. Life Sci 1980;27:2211–7.

22.

22. Manara

Bianchi

Ferretti

Tavani

. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther 1986;237:945–9.

23.

23. Cohn

Huntington

Byrd

Machado

Cohn

. Epidural morphine and methylprednisolone. New therapy for recurrent low-back pain. Spine 1986;11:960–3.

24.

24. Green

. Comparative effects of analgesics on pain threshold, respiratory frequency and gastrointestinal propulsion. Br J Pharmacol Chemother 1959;14:26–34.

25.

25. Niemegeers

Lenaerts

Awouters

. Preclinical animal studies of modern antidiarrheal: In vivo pharmacology. In: Van Bever

Lal

, eds. Synthetic antidiarrheal drugs: Synthesis-preclinical and clinical pharmacology. New York: Marcel Dekker, 1976:65–114.

26.

26. Kromer

. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol Rev 1988;40:121–62.

27.

27. Ling

Paul

Simantov

Pasternak

. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci 1989;45:1627–36.

28.

28. Thompson

Ray

. The importance of opioid tolerance: A therapeutic paradox. J Am Coll Surg 2003;196:321–4.

29.

29. Pasternak

. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 2001;22:67–70.

30.

30. Tan-No

Niijima

Nakagawasai

Sato

Satoh

Tadano

. Development of tolerance to the inhibitory effect of loperamide on gastrointestinal transit in mice. Eur J Pharm Sci 2003;20:357–63.

31.

31. Mehendale

Yuan

. Opioid-induced gastrointestinal dysfunction. Dig Dis 2006;24:105–12.

32.

32. Bianchi

Fiocchi

Tavani

Manara

. Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity. Life Sci 1982;30:1875–83.

33.

33. Boscan

Van Hoogmoed

Pypendop

Farver

Snyder

. Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. Am J Ve t Res 2006;67:998–1004.

34.

34. Yuan

Foss

Moss

. Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur J Pharmacol 1995;276:107–11.

35.

35. van Hoogmoed

Boscan

. In vitro evaluation of the effect of the opioid antagonist N-methylnaltrexone on motility of the equine jejunum and pelvic flexure. Equine Ve t J 2005;37:325–8.

36.

36. Schang

Devroede

. Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am J Gastroenterol 1985;80:407–11.

37.

37. Holzer

. Opioids and opioid receptors in the enteric nervous system: From a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004;361:192–5.

38.

38. Kreek

Schaefer

Hahn

Fishman

. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet 1983;1:261–2.

39.

39. Hawkes

Rhodes

Evans

Rhodes

Hawthorne

Thomas

. Naloxone treatment for irritable bowel syndrome—a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002;16:1649–54.

40.

40. Yuan

Israel

. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 2006;15:541–52.

41.

41. Bond

Jr Levitt

Prentiss

. Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H₂) measurements. J Lab Clin Med 1975;85:546–55.

42.

42. Read

Al-Janabi

Bates

. Interpretation of the breath hydrogen profile obtained after ingesting a solid meal containing unabsorbable carbohydrate. Gut 1985;26:834–42.

43.

43. Yuan

Foss

O'Connor

Toledano

Roizen

Moss

. Methylnaltrexone prevents morphine-induced delay in oral—cecal transit time without affecting analgesia: A double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996;59:469–75.

44.

44. Yuan

Karrison

Lowell

Lynch

Foss

. Dose-related effects of oral acetaminophen on cold-induced pain: A double-blind, randomized, placebo-controlled trial. Clin Pharmacol Ther 1998;63:379–83.

45.

45. Yuan

Foss

O'Connor

. Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. JAMA 2000;283:367–72.

46.

46. Yuan

Foss

O'Connor

Osinski

Roizen

Moss

. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: A pilot study. Pain 1999;83:631–5.

47.

47. Thomas

Lipman

Slatkin

. A phase III double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness (AMI) (abstract). Proc Am Soc Clin Oncol 2005;25:8003.

48.

48. Slatkin

Karver

Thomas

. A Phase III double-blind, placebo-controlled trial of methylnaltrexone for opioid-induced constipation in advanced illness (MNTX 302). Digest Dis Week 2006686e.

49.

49. Campora

Merlini

Pace

. The incidence of narcotic-induced emesis. J Pain Symptom Manage 1991;6:428–30.

50.

50. Aparasu

McCoy

Weber

Mair

Parasuraman

. Opioid-in-duced emesis among hospitalized nonsurgical patients: Effect on pain and quality of life. J Pain Symptom Manage 1999;18:280–8.

51.

51. Blancquaert

J P

Lefebvre

Willems

. Emetic and antiemetic effects of opioids in the dog. Eur J Pharmacol 1986;128:143–50.

52.

52. Bhandari

Bingham

Andrews

. The neuropharmacology of loperamide-induced emesis in the ferret: The role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacology 1992;31:735–42.

53.

53. Foss

Bass

Goldberg

. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharmacol 1993;33:747–51.

54.

54. Bhargava

Dixit

Gupta

. Enkephalin receptors in the emetic chemoreceptor trigger zone of the dog. Br J Pharmacol 1981;72:471–5.

55.

55. Foss

Yuan

Roizen

Goldberg

. Prevention of apomorphine-or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol 1998;42:287–91.

56.

56. Kohl

MacDonald

. New pharmacologic approaches to the prevention of space/motion sickness. J Clin Pharmacol 1991;31:934–46.

57.

57. Bueno

Fioramonti

. Action of opiates on gastrointestinal function. Baillieres Clin Gastroenterol 1988;2:123–39.

58.

58. Improta

Broccardo

. Effect of selective mu 1, mu 2 and delta 2 opioid receptor agonists on gastric functions in the rat. Neuropharmacology 1994;33:977–81.

59.

59. Murphy

Sutton

Prescott

Murphy

. Opioid-induced delay in gastric emptying: A peripheral mechanism in humans. Anesthesiology 1997;87:765–70.

60.

60. Yuan

Foss

O'Connor

Roizen

Moss

. Effects of low-dose morphine on gastric emptying in healthy volunteers. J Clin Pharmacol 1998;38:1017–20.

61.

61. Sullivan

Lamki

Corcoran

. Inhibition of gastric emptying by enkephalin analogue. Lancet 1981;2:86–7.

62.

62. Sullivan

. The pharmacologic effects of naloxone and an enkephalin analogue on human upper gastrointestinal motility and secretion. In: Fraioli

Isidori

Mazzetti

, eds. Opioid peptides in the periphery. New York: Elsevier Science Publishers, 1984:213–24.

63.

63. Shea-Donohue

Adams

Arnold

Dubois

. Effects of metenkephalin and naloxone on gastric emptying and secretion in rhesus monkeys. Am J Physiol 1983;245:G196–200.

64.

64. Kostritsky-Pereira

Woussen-Colle

De Graef

. Effects of morphine, enkephalins and naloxone on postprandial gastric acid secretion, gastric emptying and gastrin release in dogs. Arch Int Physiol Biochim 1984;92:19–26.

65.

65. Touzeau

Shea-Donohue

. Kappa agonists inhibit gastric emptying but not acid secretion in rhesus monkeys. J Pharmacol Exp Ther 1990;253:1010–6.

66.

66. Gue

Fioramonti

Honde

Pascaud

Junien

Bueno

. Opposite effects of kappa-opioid agonists on gastric emptying of liquids and solids in dogs. Gastroenterology 1988;95:927–31.

67.

67. Gue

Junien

Bueno

. Central and peripheral opioid modulation of gastric relaxation induced by feeding in dogs. J Pharmacol Exp Ther 1989;250:1006–10.

68.

68. Andrews

Wood

. Vagally mediated gastric motor and emetic reflexes evoked by stimulation of the antral mucosa in anaesthetized ferrets. J Physiol 1988;395:1–16.

69.

69. Aung

Mehendale

Xie

Moss

Yuan

. Methylnaltrexone prevents morphine-induced kaolin intake in the rat. Life Sci 2004;74: 2685–91.

70.

70. Livingston

Passaro

Jr . Postoperative ileus. Dig Dis Sci 1990;35:121–32.

71.

71. Welling

Rath

Albers

Glaser

. Gastrointestinal complications after cardiac surgery. Arch Surg 1986;121:1178–80.

72.

72. Benacker

. Managing quality on an orthopedic service: Ileus in the lumbar spinal fusion patient. J Healthc Qual 1993;15:17–20.

73.

73. Luckey

Livingston

Tache

. Mechanisms and treatment of postoperative ileus. Arch Surg 2003;138:206–14.

74.

74. Huge

Kreis

Zittel

Becker

Starlinger

Jehle

. Postoperative colonic motility and tone in patients after colorectal surgery. Dis Colon Rectum 2000;43:932–9.

75.

75. Basse

Jakobsen

D Hjort

Billesbolle

Werner

Kehlet

. A clinical pathway to accelerate recovery after colonic resection. Ann Surg 2000;232:51–7.

76.

76. Kurz

Sessler

. Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. Drugs 2003;63:649–71.

77.

77. Le Blanc-Louvry

Coquerel

Koning

Maillot

Ducrotte

. Operative stress response is reduced after laparoscopic compared to open cholecystectomy: The relationship with postoperative pain and ileus. Dig Dis Sci 2000;45:1703–13.

78.

78. De Winter

Boeckxstaens

De Man

Moreels

Herman

Pelckmans

. Effect of adrenergic and nitrergic blockade on experimental ileus in rats. Br J Pharmacol 1997;120:464–8.

79.

79. Viscusi

Rathmell

Alessandro

Gan

Israel

. A double-blind, randomized, placebo-controlled trial of methylnaltrexone (MNTX) for post-operative bowel dysfunction in segmental colectomy patients. Proc Am Soc Anesth 20051630. Anesthesiology 2005;103:A893.

80.

80. Taguchi

Sharma

Saleem

. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 2001;345:935–40.

81.

81. Chakravarty

Matallana

Jensen

Borison

. Central effects of antitussive drugs on cough and respiration. J Pharmacol Exp Ther 1956;117:127–35.

82.

82. Adcock

Schneider

Smith

. Effects of codeine, morphine and a novel opioid pentapeptide BW443C, on cough, nociception and ventilation in the unanaesthetized guinea-pig. Br J Pharmacol 1988;93:93–100.

83.

83. Amin

Sopchak

Foss

Esposito

Roizen

Camporesi

. Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. Anesth Analg 1994;78:701–5.

84.

84. Borison

Wang

. Physiology and pharmacology of vomiting. Pharmacol Rev 1953;5:193–230.

85.

85. Levy

Brister

Shearin

. Wheal and flare responses to opioids in humans. Anesthesiology 1989;70:756–60.

86.

86. Barke

Hough

. Opiates, mast cells and histamine release. Life Sci 1993;53:1391–9.

87.

87. Gordon

Myers

Blumer

. In vitro evaluation of the potential role of sulfite radical in morphine-associated histamine release. BMC Pharmacol 2004;4:21.

88.

88. Yuan

Foss

O'Connor

Osinski

Roizen

Moss

. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 1998;52:161–5.